Categories: News

closerlook Bolsters Its Multichannel Marketing Services: Adds Alecia Dantico And Expands Its Team

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

CHICAGO, May 2, 2019 /PRNewswire/ — Lead agency closerlook, inc., bolsters its multichannel marketing (MCM) services with the addition of Alecia Dantico as VP, MCM strategy.

Alecia Dantico is VP of multichannel marketing, strategyAlecia Dantico is VP of multichannel marketing, strategy

Dantico comes to the agency with more than 15 years of experience leading, building and executing MCM strategies in multiple industries, including pharma. At closerlook, she will play a key role in enhancing the agency’s MCM offering and in bringing brand messages to life in the right combination of channels to drive conversion.

Alecia Dantico’s addition marks the agency’s movement to differentiate itself,” said Ryan Mason, chief creative officer. “Clients have been tapping our strategic services to launch brands and execute multichannel programs. With Alecia on the strategy team, we can expand our offerings to include more robust MCM strategy with particular focus in consumer, social and shopper marketing. This combination of expertise—pharma and MCM strategies—benefits brands, clients and most importantly, customers.”

Prior to joining closerlook, Dantico served as VP, head of social media and influencer marketing at Mirum agency, a “borderless” digital firm and part of holding company WPP. Her integrated marketing expertise comes from having worked for Inspira Marketing Group, Allison Partners PR agency and healthcare advocacy firm Discovery USA.

Dantico holds multiple degrees and is an adjunct professor of social media and digital marketing communications at Roosevelt University in Chicago.  

ABOUT CLOSERLOOK, INC.
Established in 1987, closerlook is new type of lead agency that combines biopharma brand marketing, digital marketing and marketing analytics to help biopharmaceutical companies promote new therapies that help improve the lives of patients and those who care for them. With offices in Chicago and New York, closerlook has won multiple awards for its unique ability to create engagement and foster loyalty through consulting, brand and creative strategy, multichannel marketing and marketing intelligence. For more information, contact 312-640-3700 or visit the website at closerlook.com.

CONTACT INFORMATION
Marita Gomez
630-936-9105

View original content to download multimedia:http://www.prnewswire.com/news-releases/closerlook-bolsters-its-multichannel-marketing-services-adds-alecia-dantico-and-expands-its-team-300842404.html

SOURCE closerlook, inc.

Staff

Recent Posts

TriSalus Life Sciences Announces Publication of Safety and Efficacy Results for a Novel Pressure-Enabled Thyroid Embolization Technique

WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences® Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), an oncology company…

3 hours ago

TriSalus Life Sciences Announces Publication of Safety and Efficacy Results for a Novel Pressure-Enabled Thyroid Embolization Technique

WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences® Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), an oncology company…

3 hours ago

SetPoint Medical Raises $140 Million in Private Financing and Expands Leadership Team to Support Commercialization of Rheumatoid Arthritis Therapy

VALENCIA, Calif.--(BUSINESS WIRE)--SetPoint Medical, a company dedicated to developing therapies for people living with chronic…

3 hours ago

SetPoint Medical Raises $140 Million in Private Financing and Expands Leadership Team to Support Commercialization of Rheumatoid Arthritis Therapy

VALENCIA, Calif.--(BUSINESS WIRE)--SetPoint Medical, a company dedicated to developing therapies for people living with chronic…

3 hours ago

Windtree Announces Istaroxime has been Chosen for a Plenary Session Presentation at the Heart Failure Society of America 2025

Presentation will be the interim data from the Phase 2 study of istaroxime in SEISMiC…

3 hours ago

FDA Approves Tiziana Life Sciences Phase 2 IND for Multiple System Atrophy

NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”…

3 hours ago